Li Yang1, Dushani L Palliyaguru2, Thomas W Kensler3. 1. Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2. Department of Environmental and Occupational Health, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261. 3. Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Environmental and Occupational Health, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261. Electronic address: tkensler@pitt.edu.
Abstract
With the properties of efficacy, safety, tolerability, practicability and low cost, foods containing bioactive phytochemicals are gaining significant attention as elements of chemoprevention strategies against cancer. Sulforaphane [1-isothiocyanato-4-(methylsulfinyl)butane], a naturally occurring isothiocyanate produced by cruciferous vegetables such as broccoli, is found to be a highly promising chemoprevention agent against not only a variety of cancers such as breast, prostate, colon, skin, lung, stomach or bladder, but also cardiovascular disease, neurodegenerative diseases, and diabetes. For reasons of experimental exigency, preclinical studies have focused principally on sulforaphane itself, while clinical studies have relied on broccoli sprout preparations rich in either sulforaphane or its biogenic precursor, glucoraphanin. Substantive subsequent evaluation of sulforaphane pharmacokinetics and pharmacodynamics has been undertaken using either pure compound or food matrices. Sulforaphane affects multiple targets in cells. One key molecular mechanism of action for sulforaphane entails activation of the Nrf2-Keap1 signaling pathway although other actions contribute to the broad spectrum of efficacy in different animal models. This review summarizes the current status of pre-clinical chemoprevention studies with sulforaphane and highlights the progress and challenges for the application of foods rich in sulforaphane and/or glucoraphanin in the arena of clinical chemoprevention.
With the properties of efficacy, safety, tolerability, practicability and low cost, foods containing bioactive phytochemicals are gaining significant attention as elements of chemoprevention strategies against n class="Disease">cancer. Sulforaphane[1-isothiocyanato-4-(methylsulfinyl)butane], a naturally occurring isothiocyanate produced by cruciferous vegetables such as broccoli, is found to be a highly promising chemoprevention agent against not only a variety of cancers such as breast, prostate, colon, skin, lung, stomach or bladder, but also cardiovascular disease, neurodegenerative diseases, and diabetes. For reasons of experimental exigency, preclinical studies have focused principally on sulforaphane itself, while clinical studies have relied on broccoli sprout preparations rich in either sulforaphane or its biogenic precursor, glucoraphanin. Substantive subsequent evaluation of sulforaphane pharmacokinetics and pharmacodynamics has been undertaken using either pure compound or food matrices. Sulforaphane affects multiple targets in cells. One key molecular mechanism of action for sulforaphane entails activation of the Nrf2-Keap1 signaling pathway although other actions contribute to the broad spectrum of efficacy in different animal models. This review summarizes the current status of pre-clinical chemoprevention studies with sulforaphane and highlights the progress and challenges for the application of foods rich in sulforaphane and/or glucoraphanin in the arena of clinical chemoprevention.
Authors: Sunga Choi; Karen L Lew; Hui Xiao; Anna Herman-Antosiewicz; Dong Xiao; Charles K Brown; Shivendra V Singh Journal: Carcinogenesis Date: 2006-08-18 Impact factor: 4.944
Authors: Praveen Rajendran; Ariam I Kidane; Tian-Wei Yu; Wan-Mohaiza Dashwood; William H Bisson; Christiane V Löhr; Emily Ho; David E Williams; Roderick H Dashwood Journal: Epigenetics Date: 2013-04-26 Impact factor: 4.528
Authors: Shivendra V Singh; Renaud Warin; Dong Xiao; Anna A Powolny; Silvia D Stan; Julie A Arlotti; Yan Zeng; Eun-Ryeong Hahm; Stanley W Marynowski; Ajay Bommareddy; Dhimant Desai; Shantu Amin; Robert A Parise; Jan H Beumer; William H Chambers Journal: Cancer Res Date: 2009-02-17 Impact factor: 12.701
Authors: Rex Munday; Paulette Mhawech-Fauceglia; Christine M Munday; Joseph D Paonessa; Li Tang; John S Munday; Carolyn Lister; Paula Wilson; Jed W Fahey; Warren Davis; Yuesheng Zhang Journal: Cancer Res Date: 2008-02-29 Impact factor: 12.701
Authors: Yonggang Wang; Zhiguo Zhang; Wanqing Sun; Yi Tan; Yucheng Liu; Yang Zheng; Quan Liu; Lu Cai; Jian Sun Journal: Oxid Med Cell Longev Date: 2014-02-23 Impact factor: 6.543
Authors: Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump Journal: Bladder Cancer Date: 2018-10-03
Authors: Pramod Upadhyaya; Adam T Zarth; Naomi Fujioka; Vincent A Fritz; Stephen S Hecht Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2017-12-02 Impact factor: 3.205
Authors: Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi Journal: Mol Nutr Food Res Date: 2018-08-29 Impact factor: 5.914